Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline
Assessment and Market Forecasts to 2018
Published on October 2011

Report Summary

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline
Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global BPH market.
The report identifies the key trends shaping and driving the global BPH market. The report also provides insights on the prevalent
competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the global BPH sector. This report is built using
data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's
team of industry experts.

GlobalData's analysis suggests that the global benign prostatic hyperplasia (BPH) therapeutics market was worth $3.2 billion in 2010.
It is forecast to grow at a compound annual growth rate (CAGR) of 6.4% for the next eight years to reach $5.2 billion by 2018. This
growth rate is primarily attributed to the recent and impending patent expiry of Uroxatral and Avodart/Avolve in the US and the EU.
However, the strong pipeline is set to offset the depleting revenues with the expected launch of Cialis and NX-1207 in the near future.
The increase in elderly population is expected to be a major driver of the BPH therapeutics market.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the BPH market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) BPH market revenues data from 2005 to 2010,
forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by
seven key markets. Pipeline candidates fall under major therapeutic classes such as phosphodiesterase-5 (PDE5) inhibitors,
apoptosis inducers, estrogen receptor agonist and vasopressin agonist.
- Analysis of the current and future competition in the seven key countries BPH market. Key market players covered are Eli Lilly,
Nippon Shinyaku, Nymox Pharmaceutical and Bayer AG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the BPH
therapeutics market.
- Analysis of key recent licensing and partnership agreements in BPH market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8


- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global BPH market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global BPH market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global BPH market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 6
2 Benign Prostatic Hyperplasia Therapeutics: Executive Summary 8
2.1 The Benign Prostatic Hyperplasia Therapeutics Market is Forecast to Show Modest Growth Until 2018 8
2.2 Benign Prostatic Hyperplasia Therapeutics Market has Strong Competition Between Several Generics and a Few Branded
Products 9
2.3 Strong Clinical Pipeline with Several First-in-Class Molecules 9
2.4 Benign Prostatic Hyperplasia Therapeutic Market has Moderate Unmet Need 9
3 Benign Prostatic Hyperplasia (BPH): Introduction 11
3.1 Disease Overview 11
3.2 Epidemiology 12
3.3 Pathophysiology 12
3.4 Symptoms 13
3.5 Diagnosis 13
3.6 Treatment 14
3.6.1 Alpha Blockers 14
3.6.2 5-Alpha Reductase Inhibitors 15
3.6.3 Combination Therapy 15
3.6.4 Anticholinergics 15
3.6.5 Surgery 16
3.7 GlobalData Pipeline Report Guidance 16
4 Benign Prostatic Hyperplasia Therapeutics: Market Characterization 18
4.1 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' Global 18
4.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' Global 20
4.3 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' The US 21
4.4 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' The US 22
4.5 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' The UK 24
4.6 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' The UK 25
4.7 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' France 26



4.8 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' France 28
4.9 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' Germany 29
4.10 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' Germany 30
4.11 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' Italy 31
4.12 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' Italy 33
4.13 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' Spain 34
4.14 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' Spain 35
4.15 Benign Prostatic Hyperplasia Therapeutics Market Size (2005-2010) ' Japan 36
4.16 Benign Prostatic Hyperplasia Therapeutics Market Forecast (2010-2018) ' Japan 38
4.17 Drivers and Barriers for the Benign Prostatic Hyperplasia Therapeutics Market 39
4.17.1 Drivers for the Benign Prostatic Hyperplasia Therapeutics Market 39
4.17.2 Barrier for the Benign Prostatic Hyperplasia Therapeutics Market 40
4.18 Opportunity and Unmet Need Analysis 40
4.19 Key Takeaway 41
5 Benign Prostatic Hyperplasia Therapeutics: Competitive Assessment 43
5.1 Overview 43
5.2 Strategic Competitor Assessment 43
5.3 Product Profiles for the Major Marketed Products in the Benign Prostatic Hyperplasia Therapeutics Market 44
5.3.1 Duodart (fixed dose combination of Avodart (dutasteride) and tamsulosin) 44
5.3.2 Alfuzosin (Xatral/ Uroxatral) 46
5.3.3 Tamsulosin (Flomax, Harnal) 47
5.3.4 Terazosin (Hytrin) 49
5.3.5 Finasteride (Proscar) 50
5.3.6 Doxazosin (Cardura, Cardura XL) 52
5.3.7 Avodart/Avolve (Dutasteride) 53
5.3.8 Silodosin (Rapaflo / Urief) 55
5.4 Key Takeaway 56
6 Benign Prostatic Hyperplasia Therapeutics: Pipeline Assessment 57
6.1 Overview 57
6.2 Strategic Pipeline Assessment 57
6.2.1 Benign Prostatic Hyperplasia Therapeutics ' Pipeline by Phases of Development 57
6.2.2 Benign Prostatic Hyperplasia Therapeutics ' Pre-Registration Pipeline 58
6.2.3 Benign Prostatic Hyperplasia Therapeutics ' Phase III Pipeline 58
6.2.4 Benign Prostatic Hyperplasia Therapeutics ' Phase II Pipeline 58
6.2.5 Benign Prostatic Hyperplasia Therapeutics ' Phase I Pipeline 59
6.2.6 Benign Prostatic Hyperplasia Therapeutics ' Preclinical Pipeline 59
6.2.7 Technology Trends Analytical Framework 59
6.2.8 Technology Trend Analytical Framework Description 60
6.3 Benign Prostatic Hyperplasia Therapeutics ' Clinical Pipeline by Mechanism of Action 61
6.4 Benign Prostatic Hyperplasia Therapeutics ' Promising Drugs with Novel Mechanisms of Action under Clinical Development 62
6.5 Profiles of Promising Drugs under Clinical Development 63
6.5.1 Cialis (tadalafil) 63
6.5.2 NX-1207 64
6.6 Key Takeaway 65
7 Benign Prostatic Hyperplasia Therapeutics: Clinical Trials Mapping 67
7.1 Clinical Trials by Country 67
7.2 Clinical Trials by Phase 68
7.3 Clinical Trials by Trial Status 69



7.4 Prominent Sponsors 71
7.5 Prominent Sponsors 72
7.6 Top Companies Participating in Therapeutics Clinical Trials 73
8 Benign Prostatic Hyperplasia Therapeutics: Strategic Assessment 75
8.1 Key Events Impacting the Future Market 75
8.2 Implications for Future Market Competition 75
9 Benign Prostatic Hyperplasia Therapeutics: Future Players 78
9.1 Introduction 78
9.2 Company Profiles 79
9.2.1 Eli Lilly and Company 79
9.2.2 Nymox Pharmaceutical Corporation 80
10 Benign Prostatic Hyperplasia(MM) Therapeutics: Licensing and Partnership Deals 83
11 Benign Prostatic Hyperplasia Therapeutics: Appendix 90
11.1 Market Definitions 90
11.2 Abbreviations 90
11.3 Methodology 92
11.3.1 Coverage 92
11.3.2 Secondary Research 92
11.3.3 Forecasting 93
11.3.4 Primary Research 95
11.3.5 Expert Panel Validation 96
11.4 Contact Us 96
11.5 Disclaimer 96
11.6 Bibliography 97

List of Tables

Table 1: Benign Prostatic Hyperplasia (BPH), Prevalence, Seven Major Markets, 2010 12
Table 2: Benign Prostatic Hyperplasia Therapeutics Market, Global, Revenue ($bn), 2005'2010 19
Table 3: Benign Prostatic Hyperplasia Therapeutics Market, Global, Forecast ($bn), 2010'2018 20
Table 4: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue ($bn), 2005'2010 22
Table 5: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue ($bn), 2005'2010 23
Table 6: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Revenue ($m), 2005'2010 25
Table 7: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Forecast ($m), 2010'2018 26
Table 8: Benign Prostatic Hyperplasia Therapeutics Market, France, Revenue ($m), 2005'2010 27
Table 9: Benign Prostatic Hyperplasia Therapeutics Market, France, Forecast ($m), 2010'2018 29
Table 10: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Revenue ($m), 2005'2010 30
Table 11: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Forecast ($m), 2010'2018 31
Table 12: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Revenue ($m), 2005'2010 32
Table 13: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Forecast ($m), 2010'2018 34
Table 14: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Revenue ($m), 2005'2010 35
Table 15: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Forecast ($m), 2010'2018 36
Table 16: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Revenue ($m), 2005'2010 37
Table 17: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Forecast ($m), 2010'2018 38
Table 18: Benign Prostatic Hyperplasia Therapeutics ' Pre-Registration Pipeline 58
Table 19: Benign Prostatic Hyperplasia Therapeutics ' Phase III Pipeline 58
Table 20: Benign Prostatic Hyperplasia Therapeutics ' Phase II Pipeline 59
Table 21: Benign Prostatic Hyperplasia Therapeutics ' Phase I Pipeline 59



Table 22: Benign Prostatic Hyperplasia Therapeutics ' Preclinical Pipeline 59
Table 23: Benign Prostatic Hyperplasia Therapeutics ' Promising Drugs Under Clinical development, 2011 62
Table 24: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Country, 2011 68
Table 25: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Phase, 2011 69
Table 26: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Status, 2011 70
Table 27: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Overall Sponsors, 2011 71
Table 28: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Prominent Sponsors, 2011 73
Table 29: Eli Lilly and Company ' Genitourinary Pipeline, 2011 80
Table 30: Nymox Pharmaceutical Corporation ' Genitourinary Pipeline, 2010 82
Table 31: Benign Prostatic HyperplasiaTherapeutics, Global, Deals, 2011 84

List of Figures

Figure 1: BPH Therapeutics Market, Global, Revenues and Market Forecast ($bn), 2005'2018 8
Figure 2: Opportunity and Unmet Need in the BPH Therapeutics Market, 2011 10
Figure 3: Benign Prostatic Hyperplasia (BPH) 12
Figure 4: Benign Prostatic Hyperplasia Therapeutics Market, Global, Revenue ($bn), 2005'2010 18
Figure 5: Benign Prostatic Hyperplasia Therapeutics, Market Share ($m), 2010 19
Figure 6: Benign Prostatic Hyperplasia Therapeutics Market, Global, Forecast ($bn), 2010'2018 20
Figure 7: Benign Prostatic Hyperplasia Therapeutics, Market Share ($m), 2018 21
Figure 8: Benign Prostatic Hyperplasia Therapeutics Market, The US, Revenue ($bn), 2005'2010 21
Figure 9: Benign Prostatic Hyperplasia Therapeutics Market, The US, Forecast ($bn), 2010'2018 23
Figure 10: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Revenue ($m), 2005'2010 24
Figure 11: Benign Prostatic Hyperplasia Therapeutics Market, The UK, Forecast ($m), 2010'2018 25
Figure 12: Benign Prostatic Hyperplasia Therapeutics Market, France, Revenue ($m), 2005'2010 27
Figure 13: Benign Prostatic Hyperplasia Therapeutics Market, France, Forecast ($m), 2010'2018 28
Figure 14: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Revenue ($m), 2005'2010 29
Figure 15: Benign Prostatic Hyperplasia Therapeutics Market, Germany, Forecast ($m), 2010'2018 30
Figure 16: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Revenue ($m), 2005'2010 32
Figure 17: Benign Prostatic Hyperplasia Therapeutics Market, Italy, Forecast ($m), 2010'2018 33
Figure 18: Benign Prostatic Hyperplasia Therapeutics Market, Spain, Revenue ($m), 2005'2010 34
Figure 19: Benign Prostatic HyperplasiaTherapeutics Market, Spain, Forecast ($m), 2010'2018 35
Figure 20: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Revenue ($m), 2005'2010 37
Figure 21: Benign Prostatic Hyperplasia Therapeutics Market, Japan, Forecast ($m), 2010'2018 38
Figure 22: Opportunity and Unmet Need in the BPH Therapeutics Market, 2011 41
Figure 23: Strategic Competitor Assessment of the Marketed Products for BPH Therapeutics,2011 44
Figure 24: Benign Prostatic Hyperplasia Therapeutics Pipeline by Phase of Clinical Development, 2011 58
Figure 25: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline, 2011 60
Figure 26: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline ' Description, 2010 60
Figure 27: Benign Prostatic Hyperplasia Therapeutics ' Pipeline by Mechanism of Action, 2011 61
Figure 28: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Country, 2011 67
Figure 29: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Phase, 2011 68
Figure 30: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Status, 2011 70
Figure 31: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Overall Sponsors, 2011 71
Figure 32: Benign Prostatic Hyperplasia Therapeutics ' Clinical Trials by Prominent Sponsors, 2011 72
Figure 33: Benign Prostatic Hyperplasia ' Clinical Trials by Top Sponsors, 2011 73
Figure 34: Benign Prostatic Hyperplasia Therapeutics Market, Drivers and Barriers, 2011 75
Figure 35: Implications for Future Market Competition in Benign Prostatic Hyperplasia Therapeutic Market, 2011 75



Figure 36: Benign Prostatic Hyperplasia Therapeutics ' Pipeline by Company, 2011 78
Figure 37: GlobalData Market Forecasting Model 94Eli Lilly and Company
Nymox Pharmaceutical Corporation


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018